Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer-Reference-Cited by-同舟云学术

Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer

Published:2018-01 Issue:1 Volume:36 Page:8.e17-8.e24
ISSN:1078-1439
Container-title:Urologic Oncology: Seminars and Original Investigations
language:en
Short-container-title:Urologic Oncology: Seminars and Original Investigations

Author:

Rieken Malte,Shariat Shahrokh F.,Kluth Luis,Crivelli Joseph J.,Abufaraj Mohammad^ORCID,Foerster Beat,Mari Andrea,Ilijazi Dafina,Karakiewicz Pierre I.,Babjuk Marek,Gönen Mithat,Xylinas Evanguelos

Publisher

Elsevier BV

Subject

Urology,Oncology

Reference18 articles.

1. Treatment of muscle-invasive and metastatic bladder cancer: update of the EAU guidelines;Stenzl;Eur Urol,2011

2. Cancer statistics;Siegel;CA Cancer J Clin,2016

3. Babjuk M, Burger M, Zigeuner R, et al. Guidelines on non-muscle-invasive bladder cancer (TaT1 and CIS). Uroweb. Available at: http://www.uroweb.org/gls/pdf05_TaT1_Bladder_Cancer_LR.pdf; 2013.

4. EAU guidelines on non–muscle-invasive urothelial carcinoma of the bladder: update 2016;Babjuk;Eur Urol,2017

5. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials;Sylvester;Eur Urol,2006

Cited by 38 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Surveillance for Nonmuscle Invasive Bladder Cancer: Identifying the Point of Diminishing Returns;Urology;2023-11

2. Assessing the Performance of 18F-FDG PET/CT in Bladder Cancer: A Narrative Review of Current Evidence;Cancers;2023-05-28

3. French AFU Cancer Committee Guidelines - Update 2022-2024: Non-muscle-invasive bladder cancer (NMIBC);Progrès en Urologie;2022-11

4. Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy;Diagnostics;2022-02-25

5. Treatment Outcomes of High-Risk Non-Muscle Invasive Bladder Cancer (HR-NMIBC) in Real-World Evidence (RWE) Studies: Systematic Literature Review (SLR);ClinicoEconomics and Outcomes Research;2022-01